Literature DB >> 17948980

Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.

Marcela Krecmerová1, Antonín Holý, Radek Pohl, Milena Masojídková, Graciela Andrei, Lieve Naesens, Johan Neyts, Jan Balzarini, Erik De Clercq, Robert Snoeck.   

Abstract

Reaction of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine (1) with dicyclohexylcarbodiimide and N,N,-dicyclohexyl-4-morpholinocarboxamidine in dimethylformamide at elevated temperature afforded the corresponding cyclic phosphonate 2, that is, 1-{[(5S)-2-hydroxy-2-oxido-1,4,2-dioxaphosphinan-5-yl]methyl}-5-azacytosine. Compound 2 exerts strong in vitro activity against DNA viruses, comparable with activity of parent compound 1. Transformation of 2 to its tetrabutylammonium salt followed by reaction with alkyl or acyloxyalkyl halogenides enabled us to prepare a series of structurally diverse ester prodrugs: alkyl (octadecyl), alkenyl (erucyl), alkoxyalkyl (hexadecyloxyethyl), and acyloxyalkyl (pivaloyloxymethyl) (3-6). The introduction of an alkyl, alkoxyalkyl, or acyloxyalkyl ester group to the molecule resulted in an increase of antiviral activity; the most active compound was found to be the hexadecyloxyethyl ester 5. The relative configuration of the diastereoisomer trans-6 was determined using H,H-NOESY NMR.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17948980     DOI: 10.1021/jm0707166

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

Review 1.  Synthesis of nucleoside phosphate and phosphonate prodrugs.

Authors:  Ugo Pradere; Ethel C Garnier-Amblard; Steven J Coats; Franck Amblard; Raymond F Schinazi
Journal:  Chem Rev       Date:  2014-08-21       Impact factor: 60.622

2.  Alkoxylalkyl Esters of Nucleotide Analogs Inhibit Polyomavirus DNA Replication and Large T Antigen Activities.

Authors:  Nichodemus O Onwubiko; Suraya A Diaz; Marcela Krečmerová; Heinz Peter Nasheuer
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

3.  Structure of cyclic nucleoside phosphonate ester prodrugs: an inquiry.

Authors:  Ivan S Krylov; Valeria M Zakharova; Michaela Serpi; Ralf Haiges; Boris A Kashemirov; Charles E McKenna
Journal:  J Org Chem       Date:  2011-11-30       Impact factor: 4.354

4.  Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art.

Authors:  Karl Y Hostetler
Journal:  Antiviral Res       Date:  2009-05       Impact factor: 5.970

5.  Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs.

Authors:  Don B Gammon; Robert Snoeck; Pierre Fiten; Marcela Krecmerová; Antonín Holý; Erik De Clercq; Ghislain Opdenakker; David H Evans; Graciela Andrei
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

6.  Antibacterial, Antitubercular and Antiviral Activity Evaluations of Some Arylidenehydrazide Derivatives Bearing Imidazo[2,1-b]thiazole Moiety.

Authors:  Nuray Ulusoy Güzeldemirci; Berin Karaman; Ömer Küçükbasmaci
Journal:  Turk J Pharm Sci       Date:  2017-08-15

7.  Cidofovir Activity against Poxvirus Infections.

Authors:  Graciela Andrei; Robert Snoeck
Journal:  Viruses       Date:  2010-12-22       Impact factor: 5.048

Review 8.  An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014.

Authors:  Erik De Clercq
Journal:  Acta Pharm Sin B       Date:  2015-11-02       Impact factor: 11.413

9.  3-Acetyloxy-2-cyano-2-(alkylaminocarbamoyl)propyl groups as biodegradable protecting groups of nucleoside 5´-mono-phosphates.

Authors:  Mikko Ora; Anne Mäntyvaara; Harri Lönnberg
Journal:  Molecules       Date:  2011-01-14       Impact factor: 4.411

10.  Ethacrynic and alpha-lipoic acids inhibit vaccinia virus late gene expression.

Authors:  Martina Spisakova; Zdenek Cizek; Zora Melkova
Journal:  Antiviral Res       Date:  2008-12-04       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.